Dr. Luke on the Combination of Pembrolizumab and T-VEC for Melanoma
Jason Luke, MD, an assistant professor of medicine at the University of Chicago Medicine, discusses the combination of pembrolizumab (Keytruda) and talimogene laherparepvec (T-VEC; Imlygic) for patients with melanoma